EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Expert Consensus on the Diagnosis and Treatment of Malignant Pericardial Mesothelioma

Qing Ji, Chunwei Xu, Qian Wang, Wenxian Wang, Zhenying Guo, Ziming Li, Zhengbo Song, Aijun Liu, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Wenfeng Fang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Gen Lin, Long Huang, Yu Chen, Jingping Yuan, Zhansheng Jiang, Feng Wang, Xingxiang Pu, Chuangzhou Rao, Dongqing Lv, Yinghua Ji, Xianbin Liang, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Xuelei Ma, Hui Guo

Med Research · 2025

DOI: 10.1002/mdr2.70003 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Primary malignant pericardial mesothelioma (PMPM), a rare pericardium‐derived malignancy, urgently requires standardized diagnostic and therapeutic protocols. This consensus, established by the Chinese Alliance of Research for Mesothelioma (ChARM) through the integration of evidence‐based research and multicenter clinical expertise, addresses the following critical aspects: The disease is characterized by insidious progression and local invasiveness with the majority of cases diagnosed at advanced stages. Current multimodal therapeutic strategies include radical surgery, platinum‐based combination chemotherapy, and precision radiotherapy. The introduction of PD‐1/PD‐L1 inhibitors has extended median survival to up to 24 months. The consensus emphasizes the diagnostic utility of multimodal imaging combined with histopathological immunohistochemical analysis. Furthermore, a stratified prognostic model incorporating tumor biomarkers is proposed to standardize follow‐up surveillance protocols, ensuring a systematic monitoring of disease progression and therapeutic efficacy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →